Bio Medica Laboratories
LISTEDIPO Date: 21 May - 25 May 2026
Listing Date: 29 May 2026
Price Range
Rs.132 - Rs.139
Issue Size
52 Cr
Min Investment
₹2,64,000
2 lots minimum (SEBI rule for SME)
Min Application
2000 Shares
1000 per lot × 2
Schedule of Bio Medica Laboratories
Issue open date
21 May 2026
Issue close date
25 May 2026
UPI mandate deadline
25 May 2026 (5 PM)
Allotment finalization
26 May 2026
Share credit
27 May 2026
Listing date
29 May 2026
Mandate end date
9 Jun 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 52 Cr |
| Fresh Issue | 47.19 Cr |
| Offer for Sale | 5.24 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 26 May 2026 |
| Allotment Link | {Link} |
Grey Market Premium
NewGrey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | IPO Price | GMP | Est. Listing Price |
|---|---|---|---|
| 26 May 2026Latest | ₹139 | ₹0 | ₹139(0%) |
| 25 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 24 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 23 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 22 May 2026 | ₹139 | ₹2 | ₹141(+1.44%) |
| 20 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 19 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 18 May 2026 | ₹139 | ₹0 | ₹139(0%) |
| 17 May 2026 | ₹139 | ₹0 | ₹139(0%) |
Performance Bio Medica Laboratories
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.132 - Rs.139 | ₹ 111 (-20%) | ₹ 158 | 13.67% |
About Bio Medica Laboratories
Bio Medica Laboratories Limited (BMLL) is a Madhya Pradesh-based company engaged in the manufacturing of pharmaceutical parenteral formulations. The company was incorporated in 2015 and converted into a public limited company in October 2024. BMLL manufactures generic drugs in the form of injectables, specifically liquid injections and dry powder injections, available in single-dose and multi-dose forms. These products cater to both human and veterinary needs. The company operates on a B2B contract manufacturing model, producing formulations for other companies as per their specific requirements, and does not sell directly to end users. The company operates from a single manufacturing facility in Madhya Pradesh. It holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificates issued by the Food and Drugs Administration, Madhya Pradesh. Its in-house laboratory is equipped with instruments including HPLC, GC, and UV-Vis Spectrophotometer for testing and quality control purposes.
| Founded in | 2015 |
| Managing director | Mr. Pradeep Mehta |
| Parent organization |
Financial Overview
Strengths
5- 1
Bio Medica manufactures generic injectable drugs for both human and veterinary use.
- 2
The company operates on a B2B contract manufacturing model with pharmaceutical companies.
- 3
Promoters have over 18 years of experience in the pharmaceutical sector.
- 4
The company offers liquid injections and dry powder injections in single and multi-dose formats.
- 5
Revenue and profitability improved significantly in FY25 compared to previous years.
Risks
5- 1
Production at Manufacturing Unit-I was suspended due to regulatory non-compliances.
- 2
The company operates from leased properties and does not own its manufacturing premises.
- 3
The business may face conflicts of interest with promoter group entities in similar businesses.
- 4
The company had a high debt-to-equity ratio in previous financial years.
- 5
Failure to renew or maintain licenses and approvals could affect operations.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 15.94 |
| Non-Institutional Investors (NIIs) | 1.27 |
| Retail Individual Investors (RIIs) | 2.92 |
| Employee | N/A |
| Total | 2.19 |